The Pharma Data

DECEMBER 31, 2020

People with severe COVID-19 have low proportions of antibodies that target the spike protein. In milder cases, the antibodies seem to do a better job of binding to the spike protein. The spike protein binds to the ACE2 receptor on human cells, which allows the virus to enter the cell.

Antibody 52

Antibody Research Bacteria Genetics 52

The Pharma Data

JUNE 19, 2022

Known as “the guardian of the genome,” p53 is a class of proteins tasked with suppressing tumor development. However, melanoma cells counter this attack by producing Murine Double Minute (MDM) proteins, which hamper the activity of p53 and prevent the pathway from being active.

Drugs 52

Drugs Protein Immune Response Scientist 52

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Freenome’s diagnostic searches for direct indication of tumors and signs of the immune system’s response, integrating genomics, transcriptomics, methylomics, and proteomics technologies.

Vaccine 53

Vaccine Vaccination Research Trials 53

pharmaphorum

SEPTEMBER 22, 2022

The beauty of that T-cell response is that you can actually access the internal parts of the virus,” Le Vert states. Osivax’s technology, oligoDOM, trains the T-cell immune response to recognise the nucleoprotein.

Vaccine 97

Vaccine Vaccination Antibody Clinical Trials 97

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

MARCH 26, 2021

PD-L1 staining is the process by which the PD-L1 protein is visualised during testing. PD-L1 is a protein expressed on tumour cells and tumour-infiltrating cells, which suppresses the immune response and enables tumour cells to avoid detection by binding to proteins on the surface of immune cells.

HR 52

HR Protein Genome Genomics 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. The team obtained sequences from the newly circulating B.1.1.7 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccine 52

Vaccine Vaccination Research Immune Response 52

The Pharma Data

MAY 4, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

Protein 52

Protein HR In-Vitro Medicine 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 40

Antibody Vaccine Vaccination Trials 40

Roots Analysis

OCTOBER 30, 2023

These RNA based therapeutics play a crucial role in protein production and regulation of gene functions. Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest.

RNA 40

RNA Vaccine Vaccination Development 40

Delveinsight

DECEMBER 13, 2020

The first approved treatment for hepatitis C was a series of protein-based injections called recombinant interferon-alfa (IFNa). Interferons are naturally occurring proteins in the body; recombinant IFNa is the protein-based drug that works to mobilize the body’s natural immune system to fight disease.

Genotype 52

Genotype FDA Approval DNA Drugs 52

Pfizer

NOVEMBER 2, 2022

The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 Hemagglutinin is a surface protein of the influenza virus which plays a role in the initiation of infection. INDICATION.

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

The Pharma Data

JUNE 30, 2021

Mismatch repair deficiency (dMMR) occurs when the proteins that repair mismatch errors in DNA replication are missing or non-functional, leading to microsatellite instability-high (MSI-H) tumors. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Genome Genomics Containment 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. Variants of B.1.1.7, 1.351 and P.1 2,3 Another variant, B.1.351, 4 Variant P.1,

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

XTalks

DECEMBER 17, 2021

While researchers are still learning more about Omicron, what we know is that it has the ability to spread quickly, has over 30 mutations in its spike protein and can impact the effectiveness of current vaccines. Young children are most affected by the deadly disease in the continent of Africa.

Life Science 98

Life Science Vaccine Vaccination Trials 98

The Pharma Data

OCTOBER 14, 2020

(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the observational PRECISION study (TNX-C002), to examine the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. About TNX-1800.

Vaccine 40

Vaccine Vaccination Development Medicine 40

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. TIGIT and PD-L1 are proteins that play a role in suppression of the immune system.

Medicine 52

Medicine Immune Response Protein Gene 52

XTalks

NOVEMBER 20, 2020

Traditional antibody tests for uncovering past infections involve detection of antigen-specific antibodies produced during an immune response against a pathogen. The Adaptive Immune System and TCRs. Hindley said it could eventually be rolled out to the public as a more sensitive method of testing for immunity.

Antibody 98

Antibody Immune Response Protein In-Vitro 98

The Pharma Data

DECEMBER 29, 2020

The vaccine — which right now is known as NVX-CoV2373 — comes in two doses and is designed to enhance the body’s immune response to the coronavirus’ distinctive spike protein. However, these antigens “cannot replicate and cannot cause COVID-19,” the NIH said in the statement. .”

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52